DNER and prostate cancer: Recently, Wang group reported the selective BRD4 degrader 137 (WWL0245, Fig. 30) with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor WNY0824226 The degrader 137 (WWL0245) could effectively induce the degradation of BRD4 and the Dmax was more than 99% in AR-positive prostate cancer cells.